RGEN

Repligen Corp

162.19

USD

-2.86

-1.74%

Sep 10, 11:27 UTC -4

Open

Repligen Corp Profile

About

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

Info & Links

CEO

Olivier Loeillot

Headquarters

41 SEYON STREET, BUILDING 1, SUITE 100
WALTHAM, MA 02453, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

198

Employees

2,000

Repligen Corp Statistics

Valuation Measures

Market Capitalization²

9.15B

Enterprise Value

9.10B

Enterprise Value/EBITDA(ttm)

56.49

Price to Earnings Ratio(ttm)

85.55

Price to Sales(ttm)

12.11

Price to Book(mrq)

4.50

Price to Cash(ytd)

49.32

Profitability

Gross Margin(ttm)

53.53%

Operating Margin(ttm)

14.20%

Profit Margin(ttm)

5.34%

Return on Equity(ttm)

5.30%

Return on Invested Capital(ttm)

1.57%

Return on Assets(ttm)

3.79%

Income Statement

Revenue(ttm)

785.10M

Revenue Per Share(ttm)

13.91

Gross Profit(ttm)

420.20M

EBITDA(ttm)³

161.03M

Net Income Available to Common(ttm)

41.54M

Diluted EPS(ttm)

0.73

Share Statistics

Beta (5Y Monthly)

1.05

52-Week Change

36.65%

S&P 500 52-Week Change

17.93%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

56.44M

Dividend Yield

0.00%

Float⁴

56.10M

% Held by Insiders

0.60%

% Held by Institutions

97.64%

Balance Sheet

Total Cash(mrq)

810.45M

Total Cash Per Share(mrq)

14.36

Total Debt(mrq)

551.05M

Total Debt/Equity(mrq)

26.09%

Current Ratio(mrq)

9.05%

Quick Ratio(mrq)

7.64%

Book Value Per Share(mrq)

37.43

Cash Flow

Operating Cash Flow Per Share(ytd)

1.08

Free Cash Flow(ytd)

50.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.